- Home
- NUVL vs GHC Comparison
NUVL vs GHC Comparison
Compare NUVL & GHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GHC
- Stock Information
- Founded
- NUVL 2017
- GHC 1877
- Country
- NUVL United States
- GHC United States
- Employees
- NUVL N/A
- GHC N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GHC Other Consumer Services
- Sector
- NUVL Health Care
- GHC Real Estate
- Exchange
- NUVL Nasdaq
- GHC Nasdaq
- Market Cap
- NUVL 5.8B
- GHC 4.8B
- IPO Year
- NUVL 2021
- GHC N/A
- Fundamental
- Price
- NUVL $80.89
- GHC $1,130.56
- Analyst Decision
- NUVL Strong Buy
- GHC
- Analyst Count
- NUVL 11
- GHC 0
- Target Price
- NUVL $120.91
- GHC N/A
- AVG Volume (30 Days)
- NUVL 429.4K
- GHC 35.7K
- Earning Date
- NUVL 08-07-2025
- GHC 10-29-2025
- Dividend Yield
- NUVL N/A
- GHC 0.64%
- EPS Growth
- NUVL N/A
- GHC 426.70
- EPS
- NUVL N/A
- GHC 155.13
- Revenue
- NUVL N/A
- GHC $4,834,649,000.00
- Revenue This Year
- NUVL N/A
- GHC $0.54
- Revenue Next Year
- NUVL N/A
- GHC $6.39
- P/E Ratio
- NUVL N/A
- GHC $7.23
- Revenue Growth
- NUVL N/A
- GHC 4.73
- 52 Week Low
- NUVL $55.54
- GHC $724.69
- 52 Week High
- NUVL $113.51
- GHC $1,125.50
- Technical
- Relative Strength Index (RSI)
- NUVL 61.76
- GHC 77.56
- Support Level
- NUVL $73.28
- GHC $1,067.00
- Resistance Level
- NUVL $81.10
- GHC $1,103.22
- Average True Range (ATR)
- NUVL 2.51
- GHC 20.77
- MACD
- NUVL 0.77
- GHC 1.17
- Stochastic Oscillator
- NUVL 83.27
- GHC 92.56
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GHC Graham Holdings Company
Graham Holdings Co. is a diversified education and media company made up of subsidiaries. Firm operations include educational services; television broadcasting; online, print, and local news; home health and hospice care; and manufacturing. The Company segments into the following seven reportable segments: Kaplan International, Higher Education, Supplemental Education, Television Broadcasting, Manufacturing, Healthcare, and Automotive. The majority of revenue comes from the Kaplan International segment, which includes higher education, test preparation, language instruction, and professional training. A large portion of company revenue also comes from the television broadcasting segment through advertising.